| Literature DB >> 33733239 |
Ahmad Al-Mrabeh1, Carl Peters1, Kieren G Hollingsworth1, Roy Taylor1.
Abstract
Liver fat content and the linked rate of export of triglyceride are central to the etiology of type 2 diabetes, as well as to the cardiovascular effects of fatty liver disease. Measurement in humans of intrahepatic and intrapancreatic fat content is described using magnetic resonance techniques and quantification of the rate of hepatic secretion of very low density lipoprotein using a non-isotopic competitive blocking of tissue uptake. This protocol is non-invasive, can be repeated sequentially, and does not involve ionizing radiation. For complete details on the use and execution of this protocol, please refer to (Taylor et al., 2018) and (Al-Mrabeh et al., 2020b).Entities:
Keywords: Clinical protocol; Metabolism
Mesh:
Substances:
Year: 2021 PMID: 33733239 PMCID: PMC7937826 DOI: 10.1016/j.xpro.2021.100355
Source DB: PubMed Journal: STAR Protoc ISSN: 2666-1667
Preparation of the density solutions for lipoprotein separation
| Reagent | Stock 1 (1.006 g/mL) | Stock 2 (1.182 g/mL) | Total volume |
|---|---|---|---|
| Solution 3 (1.0988 g/mL) | 47.5 mL | 53.0 mL | 100.5 mL |
| Solution 4 (1.0860 g/mL) | 55.0 mL | 45.8 mL | 100.8 mL |
| Solution 5 (1.0790 g/mL) | 117.5 mL | 83.1 mL | 200.8 mL |
| Solution 6 (1.0722 g/mL) | 125.0 mL | 75.4 mL | 200.4 mL |
| Solution 7 (1.0641 g/mL) | 135.0 mL | 66.5 mL | 201.5 mL |
| Solution 8 (1.0588 g/mL) | 140.0 mL | 60.0 mL | 200.0 mL |
Stock 1 (1.006 g/mL): For 1 L, add 11.4 g NaCl (0.195 M), 0.1 g Na2 EDTA (0.001%), and 1 mL NaOH (1 M), then compete the volume to 1 L with distilled water. Afterwards, add 3 mL of distilled H2O and check density of solution on analytical balance until it becomes close to 1.006 g/mL, add more distilled H2O until reaching the desired density.
Stock 2 (1.182 g/mL): add 125.5 g sodium bromide (2.44 M), and compete the volume up to 0.5 L with Stock 1 solution (1.006 g/mL).
All stock solutions can be stored at 22°C for 2–3 months, it is recommended to store in the cold room (4°C) for longer time.
Example of liver fat measurements in a person with type 2 diabetes and a non-diabetic control
| Liver Fat % | ||||||
|---|---|---|---|---|---|---|
| Slice | 1 | 2 | 3 | 4 | 5 | Average |
| T2DM | 24.8 | 23.2 | 21.2 | 20.7 | 21.4 | 22.3 |
| 1.7 | 1.7 | 0.6 | 1.4 | 1.0 | 1.3 | |
Two males aged 59 and 61 years, body weight 131.8 and 85.9 kg, with and without type 2 diabetes (T2DM/NDC), respectively, were selected. The table illustrates the expected minor variance between slices and the considerably higher liver fat levels typical of type 2 diabetes. NAFLD is defined as a liver fat content over 5.5%.
Figure 1Color map showing liver fat distribution in a person with type 2 diabetes and a non-diabetic control
Two males aged 59 and 61 years, body weight 131.8 and 85.9 kg, with and without type 2 diabetes, respectively, were studied. MR data were acquired using 3-point Dixon as explained in the programming of scanner section. Data were processed in MATLAB to create fat faction image (Figure S1). The color image was generated in MATLAB from the fat fraction image (3-point Dixon).
Example of pancreas fat measurements in a person with type 2 diabetes and matching non-diabetic control
| Pancreas Fat % | Average No Threshold % | Average with Threshold % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Slice | 1-01 | 1-02 | 1-03 | Ave. Slice1 | 2-01 | 2-02 | 2-03 | Ave. Slice2 | ||
| T2DM | 35.6 | 28.8 | 34.2 | 32.9 | 39.4 | 41.4 | 31.3 | 37.4 | 32.9 + 37.4/2=35.2 | 14.0 + 13.3/2=13.6 |
| 3.4 | 3.5 | 3.8 | 3.6 | 3.4 | 1.9 | 2.3 | 2.6 | 3.6 + 2.6/2=3.1 | 4.8 + 4.3/2=4.6 | |
Two females aged 61 and 62 years, body weight 97.4 and 68.8 kg, with and without type 2 diabetes (NDC), respectively, were studied. A subject with Type 2 diabetes (T2DM) was selected with high intrapancreatic fat content. The expected variance between slices is also illustrated to show the effect of the thresholding.
Figure 2Color map showing pancreas fat distribution in a person with type 2 diabetes and a non-diabetic control
Two females aged 61 and 62 years, body weight 97.4 and 68.8 kg, with and without type 2 diabetes (NDC), respectively, were studied. The subject with type 2 diabetes (T2DM) has high intrapancreatic fat infiltration. MR data were acquired and processed as in Figure 1, and then the color image was generated in MATLAB. The polygon tool in ImageJ was used to draw a region of interest around the borders of the pancreas (dotted yellow).
Example of raw data on VLDL1-TG production rate in a subject with type 2 diabetes in comparison with a marching non-diabetic control
| VLDL1-TG concentration (mmol/L) | Blood volume (dl) | Slope (mmol/L/min) | Fasting VLDL1-TG (mmol/l) | VLDL1-TG Production (mg/kg/day) | VLDL1-TG pool (mg) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Time point (Min) | -15 | + 0 | +15 | +45 | +60 | +75 | |||||
| 1.3 | 1.4 | 2.2 | 2.9 | 3.2 | 3.6 | 52.72 | 0.014696 | 0.675 | 741.5 | 3,117.3 | |
| 1.1 | 1.2 | 1.6 | 2 | 2.2 | 2.5 | 34.36 | 0.008662 | 0.575 | 437.0 | 1,730.7 | |
Two males aged 59 and 61 years with body weight 131.8 and 85.9 kg, with and without type 2 diabetes, respectively. T2DM: type 2 diabetes; NDC: non-diabetic control.
Figure 3Example of measuring the slope of VLDL1-TG increment during 75-min intralipid infusion in a person with type 2 diabetes and a matching non-diabetic control
Two males aged 59 and 61 years with body weight 131.8 and 85.9 kg, with and without type 2 diabetes, respectively. Intralipid was infused for 75 min, collected blood samples were processed, the VLDL1 fraction was separated, and TG content was determined. (A): Type 2 diabetes, (B) non-diabetic control. Note the steeper gradient of the line in the former, indicating a higher rate of production of VLDL1-TG.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Sodium chloride (NaCl) | Sigma-Aldrich, UK | Cat No: S9888 |
| Sodium bromide (NaBr) | Alfa Aesar, USA | Cat No: 14037 |
| Sodium hydroxide (NaOH) | VWR International, UK | Cat No: 102525P |
| Na2 EDTA | VWR International, UK | Cat No: 100935V |
| Sodium chloride (0.9%) | Fresenius Kabi, UK | Freeflex |
| Intralipid 20% | Fresenius Kabi, UK | Intralipid 20% |
| Intralipid 10% | Fresenius Kabi, UK | Intralipid 10% |
| 20% Dextrose | Fresenius Kabi, UK | 20% Dextrose |
| Infusion pump | Arcomed Infusion, UK | VP7000 PVC |
| Ultracentrifuge | Beckman Coulter, USA | Model L7-80 |
| SW40Ti rotor | Beckman Coulter, USA | PN: 331302 |
| Ultracentrifuge tubes | Seton Scientific, USA | Cat No:7031W |
| Peristaltic pump | Joyfay International, USA | BT100M |
| Glass Pasteur pipettes | VWR International, UK | Cat No: 612-1701 |
| Analytical balance | Ohaus, Switzerland | DV215CD |
| Vortex-Genie 2 | Scientific Industries UK | SI-0236 |
| Triglyceride kit | Roche Diagnostics, UK | Cat No: 05171407190 |
| Cobas modular analyzer | Roche Diagnostics, UK | cobas 8000 |
| 3T Philips Achieva scanner | Philips, Netherlands | SN: 17497 |
| Six-channel cardiac array | Philips, Netherlands | PN: 453567009711 |
| Three-point Dixon acquisition | Philips, Netherlands | mDixon |
| Balanced turbo field echo acquisition | Philips, Netherlands | BTFE |
| MATLAB | MathWorks, UK | Version R2013a |
| Processing script to produce fat fraction maps (fatcalc_direct) | Custom Script | N/A |
| Processing script to convert BTFE to Analyze 7.5 format (btfe_process) | Custom Script | N/A |
| ImageJ | National Institutes of Health, USA | Version 1.50 |